Psyence Biomedical (PBM) FDA Approvals $2.86 +0.35 (+13.94%) Closing price 11/19/2026 04:00 PM EasternExtended Trading$2.87 +0.01 (+0.35%) As of 08:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings Psyence Biomedical's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Psyence Biomedical (PBM). Over the past two years, Psyence Biomedical has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as NPX-5. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. NPX-5 FDA Regulatory Events NPX-5 is a drug developed by Psyence Biomedical for the following indication: for Adjustment Disorder. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Dosing Update - April 23,2026Dosing Update Phase 2bDrug: NPX-5Announced Date: April 23, 2026Indication: for Adjustment DisorderAnnouncementPsyence Biomedical Ltd. announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.AI SummaryPsyence Biomedical Ltd. announced the first patient has been dosed in its Phase IIb clinical trial of NPX-5 (25 mg nature-derived psilocybin) for Adjustment Disorder in patients with cancer receiving palliative care. This marks the company’s first large-scale human evaluation of NPX-5 and the start of systematic data generation across five Australian clinical sites, including centers in Perth and Melbourne. NPX-5 is described as a GMP-compliant, nature-derived psilocybin developed through PsyLabs as part of Psyence’s vertically integrated platform. The randomized, double-blind, three-arm trial will assess safety, tolerability, clinical response, and treatment durability when psilocybin is given alongside structured therapeutic support. The study’s results are intended to inform future development and potential regulatory pathways. Dr. Neil Maresky said the team is focused on disciplined execution, consistent patient recruitment, and producing high-quality data to evaluate the therapeutic potential of a 25 mg dose.Read Announcement Psyence Biomedical FDA Events - Frequently Asked Questions Has Psyence Biomedical received FDA approval? As of now, Psyence Biomedical (PBM) has not received any FDA approvals for its therapy in the last two years. What drugs has Psyence Biomedical submitted to the FDA? In the past two years, Psyence Biomedical (PBM) has reported FDA regulatory activity for NPX-5. What is the most recent FDA event for Psyence Biomedical? The most recent FDA-related event for Psyence Biomedical occurred on April 23, 2026, involving NPX-5. The update was categorized as "Dosing Update," with the company reporting: "Psyence Biomedical Ltd. announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting." What conditions do Psyence Biomedical's current drugs treat? Currently, Psyence Biomedical has one therapy (NPX-5) targeting the following condition: for Adjustment Disorder. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Adagene FDA EventsAlnylam Pharmaceuticals FDA EventsGE HealthCare Technologies FDA EventsGenprex FDA EventsHUTCHMED FDA EventsOpus Genetics FDA EventsLigand Pharmaceuticals FDA EventsEthos Technologies Inc. Class A Common Stock FDA EventsRegeneron Pharmaceuticals FDA EventsTvardi Therapeutics FDA EventsBiohaven FDA EventsJohnson & Johnson FDA EventsActuate Therapeutics FDA EventsEnlivex Therapeutics FDA EventsImmuneering FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Polyrizon FDA Events MIRA Pharmaceuticals FDA Events Incannex Healthcare FDA Events Cassava Sciences FDA Events Cocrystal Pharma FDA Events Quoin Pharmaceuticals FDA Events Tvardi Therapeutics FDA Events Quantum Biopharma FDA Events Optimi Health FDA Events Dare Bioscience FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:PBM last updated on 4/23/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dosing Update - April 23,2026Dosing Update Phase 2bDrug: NPX-5Announced Date: April 23, 2026Indication: for Adjustment DisorderAnnouncementPsyence Biomedical Ltd. announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.AI SummaryPsyence Biomedical Ltd. announced the first patient has been dosed in its Phase IIb clinical trial of NPX-5 (25 mg nature-derived psilocybin) for Adjustment Disorder in patients with cancer receiving palliative care. This marks the company’s first large-scale human evaluation of NPX-5 and the start of systematic data generation across five Australian clinical sites, including centers in Perth and Melbourne. NPX-5 is described as a GMP-compliant, nature-derived psilocybin developed through PsyLabs as part of Psyence’s vertically integrated platform. The randomized, double-blind, three-arm trial will assess safety, tolerability, clinical response, and treatment durability when psilocybin is given alongside structured therapeutic support. The study’s results are intended to inform future development and potential regulatory pathways. Dr. Neil Maresky said the team is focused on disciplined execution, consistent patient recruitment, and producing high-quality data to evaluate the therapeutic potential of a 25 mg dose.Read Announcement